(Q41729935)

8 October 2017

1 reference

title

Clinical course and therapy of chronic myelogenous leukemia with interferon-alpha and chemotherapy (English)

1 reference

8 October 2017

1 reference

Kantarjian HM

1

1 reference

8 October 2017

Giles FJ

series ordinal

2

1 reference

8 October 2017

O'Brien SM

series ordinal

3

1 reference

8 October 2017

Talpaz M

series ordinal

4

1 reference

8 October 2017

publication date

1 February 1998

1 reference

Hematology / Oncology Clinics of North America

8 October 2017

published in

1 reference

8 October 2017

volume

12

1 reference

8 October 2017

issue

1

1 reference

8 October 2017

page(s)

31-80

1 reference

UK Medical Research Council randomised, multicentre trial of interferon-alpha n1 for chronic myeloid leukaemia: improved survival irrespective of cytogenetic response. The UK Medical Research Council's Working Parties for Therapeutic Trials in Adult

8 October 2017

cites work

1 reference

https://api.crossref.org/works/10.1016%2FS0889-8588%2805%2970496-2

7 January 2021

A phase I/II study of recombinant interferon alpha 2a and hydroxyurea for chronic myelocytic leukemia

1 reference

https://api.crossref.org/works/10.1016%2FS0889-8588%2805%2970496-2

7 January 2021

Bone marrow transplantation for chronic myeloid leukaemia in first chronic phase: importance of a graft-versus-leukaemia effect.

1 reference

https://api.crossref.org/works/10.1016%2FS0889-8588%2805%2970496-2

7 January 2021

Combined interferon alfa-2a and cytosine arabinoside as first-line treatment for chronic myeloid leukemia

1 reference

https://api.crossref.org/works/10.1016%2FS0889-8588%2805%2970496-2

7 January 2021

Interferon-alpha therapy during pregnancy in chronic myelogenous leukaemia and hairy cell leukaemia

1 reference

https://api.crossref.org/works/10.1016%2FS0889-8588%2805%2970496-2

7 January 2021

Donor leukocyte infusions for chronic myeloid leukemia relapsed after allogeneic bone marrow transplantation

1 reference

https://api.crossref.org/works/10.1016%2FS0889-8588%2805%2970496-2

7 January 2021

Translocation of c-abl oncogene correlates with the presence of a Philadelphia chromosome in chronic myelocytic leukaemia

1 reference

https://api.crossref.org/works/10.1016%2FS0889-8588%2805%2970496-2

7 January 2021

The chronic myelogenous leukemia-specific P210 protein is the product of the bcr/abl hybrid gene

1 reference

https://api.crossref.org/works/10.1016%2FS0889-8588%2805%2970496-2

7 January 2021

Interferon-alpha restores normal adhesion of chronic myelogenous leukemia hematopoietic progenitors to bone marrow stroma by correcting impaired beta 1 integrin receptor function

1 reference

https://api.crossref.org/works/10.1016%2FS0889-8588%2805%2970496-2

7 January 2021

Population-based age- and sex-specific incidence rates in the 4 main types of leukaemia.

1 reference

https://api.crossref.org/works/10.1016%2FS0889-8588%2805%2970496-2

7 January 2021

Mortality from cancer and other causes after radiotherapy for ankylosing spondylitis

1 reference

https://api.crossref.org/works/10.1016%2FS0889-8588%2805%2970496-2

7 January 2021

Incidence of leukemia in Olmsted County, Minnesota, 1975 through 1989.

1 reference

https://api.crossref.org/works/10.1016%2FS0889-8588%2805%2970496-2

7 January 2021

Chronic granulocytic leukemia without the Philadelphia chromosome

1 reference

https://api.crossref.org/works/10.1016%2FS0889-8588%2805%2970496-2

7 January 2021

Long-term survivors in chronic granulocytic leukaemia: a study by the International CGL Prognosis Study Group. Italian Cooperative CML Study Group.

1 reference

https://api.crossref.org/works/10.1016%2FS0889-8588%2805%2970496-2

7 January 2021

T-cell immunity to the joining region of p210BCR-ABL protein

1 reference

https://api.crossref.org/works/10.1016%2FS0889-8588%2805%2970496-2

7 January 2021

Granulocyte colony-stimulating factor (G-CSF) induces synthesis of alkaline phosphatase in neutrophilic granulocytes of chronic myelogenous leukemia patients

1 reference

https://api.crossref.org/works/10.1016%2FS0889-8588%2805%2970496-2

7 January 2021

Donor leukocyte infusions in 140 patients with relapsed malignancy after allogeneic bone marrow transplantation

1 reference

https://api.crossref.org/works/10.1016%2FS0889-8588%2805%2970496-2

7 January 2021

Exacerbation of symptoms of autoimmune disease in patients receiving alpha-interferon therapy

1 reference

https://api.crossref.org/works/10.1016%2FS0889-8588%2805%2970496-2

7 January 2021

A pilot study of all-trans retinoic acid in patients with Philadelphia chromosome-positive chronic myelogenous leukemia

1 reference

https://api.crossref.org/works/10.1016%2FS0889-8588%2805%2970496-2

7 January 2021

Result of interferon-alpha therapy in patients with chronic myelogenous leukemia 60 years of age and older

1 reference

https://api.crossref.org/works/10.1016%2FS0889-8588%2805%2970496-2

7 January 2021

Philadelphia chromosome-negative chronic myelogenous leukemia with rearrangement of the breakpoint cluster region. Long-term follow-up results

1 reference

https://api.crossref.org/works/10.1016%2FS0889-8588%2805%2970496-2

7 January 2021

Chronic myelogenous leukemia: a review

1 reference

https://api.crossref.org/works/10.1016%2FS0889-8588%2805%2970496-2

7 January 2021

Long-term marrow culture reveals chromosomally normal hematopoietic progenitor cells in patients with Philadelphia chromosome-positive chronic myelogenous leukemia

1 reference

https://api.crossref.org/works/10.1016%2FS0889-8588%2805%2970496-2

7 January 2021

Minimal residual disease after allogeneic bone marrow transplantation for chronic myeloid leukaemia in first chronic phase: correlations with acute graft-versus-host disease and relapse

1 reference

https://api.crossref.org/works/10.1016%2FS0889-8588%2805%2970496-2

7 January 2021

Second transplants for patients with chronic myeloid leukaemia in relapse after original transplant with T-depleted donor marrow: feasibility of using busulphan alone for re-conditioning

1 reference

https://api.crossref.org/works/10.1016%2FS0889-8588%2805%2970496-2

7 January 2021

Induction of chronic myelogenous leukemia in mice by the P210bcr/abl gene of the Philadelphia chromosome

1 reference

https://api.crossref.org/works/10.1016%2FS0889-8588%2805%2970496-2

7 January 2021

Blast crisis in a murine model of chronic myelogenous leukemia

1 reference

https://api.crossref.org/works/10.1016%2FS0889-8588%2805%2970496-2

7 January 2021

A cellular oncogene is translocated to the Philadelphia chromosome in chronic myelocytic leukaemia

1 reference

https://api.crossref.org/works/10.1016%2FS0889-8588%2805%2970496-2

7 January 2021

Variant Philadelphia translocations in chronic myeloid leukemia

1 reference

https://api.crossref.org/works/10.1016%2FS0889-8588%2805%2970496-2

7 January 2021

The relevance of reticulin stain-measured fibrosis at diagnosis in chronic myelogenous leukemia

1 reference

https://api.crossref.org/works/10.1016%2FS0889-8588%2805%2970496-2

7 January 2021

Chronic myelogenous leukemia in the lymphoid blastic phase: characteristics, treatment response, and prognosis

1 reference

https://api.crossref.org/works/10.1016%2FS0889-8588%2805%2970496-2

7 January 2021

Issues in the pathology and diagnosis of the chronic myeloproliferative disorders and the myelodysplastic syndromes

1 reference

https://api.crossref.org/works/10.1016%2FS0889-8588%2805%2970496-2

7 January 2021

Philadelphia-chromosome-positive and -negative chronic myelocytic leukemia

1 reference

https://api.crossref.org/works/10.1016%2FS0889-8588%2805%2970496-2

7 January 2021

Chronic Granulocytic Leukaemia with Ph1 Negative Cells in Bone Marrow and a Ten Year Remission after Busulphan Hypoplasia

1 reference

https://api.crossref.org/works/10.1016%2FS0889-8588%2805%2970496-2

7 January 2021

Chromosomes in Ph1-positive chronic granulocytic leukemia. First International Workshop on Chromosomes in Leukaemia

1 reference

https://api.crossref.org/works/10.1016%2FS0889-8588%2805%2970496-2

7 January 2021

Recombinant human interferon (IFN) alpha-2b in chronic myelogenous leukaemia: dose dependency of response and frequency of neutralizing anti-interferon antibodies

1 reference

https://api.crossref.org/works/10.1016%2FS0889-8588%2805%2970496-2

7 January 2021

Natural killer (NK) cell immunodeficiency in patients with chronic myelogenous leukemia. II. Successful cloning and amplification of natural killer cells

1 reference

https://api.crossref.org/works/10.1016%2FS0889-8588%2805%2970496-2

7 January 2021

Relationship of the type of bcr-abl hybrid mRNA to clinical course and transforming activity in Philadelphia-positive chronic myelogenous leukemia

1 reference

https://api.crossref.org/works/10.1016%2FS0889-8588%2805%2970496-2

7 January 2021

An 8-kilobase abl RNA transcript in chronic myelogenous leukemia

1 reference

https://api.crossref.org/works/10.1016%2FS0889-8588%2805%2970496-2

7 January 2021

Busulfan (1, 4-dimethanesulfonyloxybutane, myleran); summary of clinical results

1 reference

https://api.crossref.org/works/10.1016%2FS0889-8588%2805%2970496-2

7 January 2021

Myleran in chronic myeloid leukaemia; results of treatment

1 reference

https://api.crossref.org/works/10.1016%2FS0889-8588%2805%2970496-2

7 January 2021

1 reference

https://api.crossref.org/works/10.1016%2FS0889-8588%2805%2970496-2

7 January 2021

Recombinant alpha 2B interferon in combination with oral chemotherapy in late chronic phase chronic myeloid leukaemia

1 reference

https://api.crossref.org/works/10.1016%2FS0889-8588%2805%2970496-2

7 January 2021

Recombinant alpha-interferons, thyroid irradiation and thyroid disease

1 reference

https://api.crossref.org/works/10.1016%2FS0889-8588%2805%2970496-2

7 January 2021

Effect of prior interferon alfa therapy on the outcome of allogeneic bone marrow transplantation for chronic myelogenous leukemia

1 reference

https://api.crossref.org/works/10.1016%2FS0889-8588%2805%2970496-2

7 January 2021

Splenectomy for palliation of chronic myelocytic leukemia

1 reference

https://api.crossref.org/works/10.1016%2FS0889-8588%2805%2970496-2

7 January 2021

Altered adhesive interactions with marrow stroma of haematopoietic progenitor cells in chronic myeloid leukaemia

1 reference

https://api.crossref.org/works/10.1016%2FS0889-8588%2805%2970496-2

7 January 2021

Interferon alfa-2b combined with cytarabine versus interferon alone in chronic myelogenous leukemia. French Chronic Myeloid Leukemia Study Group

1 reference

https://api.crossref.org/works/10.1016%2FS0889-8588%2805%2970496-2

7 January 2021

A multicentric randomised study of alpha 2b interferon (IFN) and hydroxyurea (HU) with or without cytosine-arabinoside (Ara-c) in previously untreated patients with Ph+ chronic myelocytic leukemia (CML): preliminary cytogenetic results

1 reference

https://api.crossref.org/works/10.1016%2FS0889-8588%2805%2970496-2

7 January 2021

Autografting for patients with CML in chronic phase: an update. Hammersmith BMT Team LRF Centre for Adult Leukaemia

1 reference

https://api.crossref.org/works/10.1016%2FS0889-8588%2805%2970496-2

7 January 2021

Cyclic leukocytosis and long survival in chronic myeloid leukemia

1 reference

https://api.crossref.org/works/10.1016%2FS0889-8588%2805%2970496-2

7 January 2021

Interferon alfa-2a as compared with conventional chemotherapy for the treatment of chronic myeloid leukemia

1 reference

https://api.crossref.org/works/10.1016%2FS0889-8588%2805%2970496-2

7 January 2021

Extramedullary presentation of the blast crisis of chronic myelogenous leukaemia

1 reference

https://api.crossref.org/works/10.1016%2FS0889-8588%2805%2970496-2

7 January 2021

Relation of “lymphoid” phenotype and response to chemotherapy incorporating vincristine-prednisolone in the acute phase of Ph1 positive leukemia

1 reference

https://api.crossref.org/works/10.1016%2FS0889-8588%2805%2970496-2

7 January 2021

The position of the M-BCR breakpoint does not predict the duration of chronic phase or survival in chronic myeloid leukemia

1 reference

https://api.crossref.org/works/10.1016%2FS0889-8588%2805%2970496-2

7 January 2021

Case report of vasopressin-responsive diabetes insipidus associated with chronic myelogenous leukemia

1 reference

https://api.crossref.org/works/10.1016%2FS0889-8588%2805%2970496-2

7 January 2021

Philadelphia chromosome-negative chronic myelogenous leukemia and chronic myelomonocytic leukemia.

1 reference

https://api.crossref.org/works/10.1016%2FS0889-8588%2805%2970496-2

7 January 2021

Treatment of advanced stages of Philadelphia chromosome-positive chronic myelogenous leukemia with interferon-alpha and low-dose cytarabine

1 reference

https://api.crossref.org/works/10.1016%2FS0889-8588%2805%2970496-2

7 January 2021

Chronic myelogenous leukemia in blast crisis. Analysis of 242 patients.

1 reference

https://api.crossref.org/works/10.1016%2FS0889-8588%2805%2970496-2

7 January 2021

Characteristics of accelerated disease in chronic myelogenous leukemia

1 reference

https://api.crossref.org/works/10.1016%2FS0889-8588%2805%2970496-2

7 January 2021

Prolonged survival in chronic myelogenous leukemia after cytogenetic response to interferon-alpha therapy. The Leukemia Service

1 reference

https://api.crossref.org/works/10.1016%2FS0889-8588%2805%2970496-2

7 January 2021

Intensive combination chemotherapy and autologous bone marrow transplantation leads to the reappearance of philadelphia chromosome-negative cells in chronic myelogenous leukemia

1 reference

https://api.crossref.org/works/10.1016%2FS0889-8588%2805%2970496-2

7 January 2021

Proposal for a simple synthesis prognostic staging system in chronic myelogenous leukemia

1 reference

https://api.crossref.org/works/10.1016%2FS0889-8588%2805%2970496-2

7 January 2021

Intensive chemotherapy induction followed by interferon-alpha maintenance in patients with Philadelphia chromosome-positive chronic myelogenous leukemia

1 reference

https://api.crossref.org/works/10.1016%2FS0889-8588%2805%2970496-2

7 January 2021

Collection of peripheral-blood diploid cells from chronic myelogenous leukemia patients early in the recovery phase from myelosuppression induced by intensive-dose chemotherapy

1 reference

https://api.crossref.org/works/10.1016%2FS0889-8588%2805%2970496-2

7 January 2021

Impact of interferon alpha-induced cytogenetic improvement on survival in chronic myelogenous leukaemia

1 reference

https://api.crossref.org/works/10.1016%2FS0889-8588%2805%2970496-2

7 January 2021

Histological classification of chronic granulocytic leukaemia

1 reference

https://api.crossref.org/works/10.1016%2FS0889-8588%2805%2970496-2

7 January 2021

Preliminary observations on the therapy of the myeloid blast phase of chronic granulocytic leukemia with plicamycin and hydroxyurea.

1 reference

https://api.crossref.org/works/10.1016%2FS0889-8588%2805%2970496-2

7 January 2021

The molecular genetics of Philadelphia chromosome-positive leukemias

1 reference

https://api.crossref.org/works/10.1016%2FS0889-8588%2805%2970496-2

7 January 2021

Rearrangement in the breakpoint cluster region and the clinical course in Philadelphia-negative chronic myelogenous leukemia

1 reference

https://api.crossref.org/works/10.1016%2FS0889-8588%2805%2970496-2

7 January 2021

Early detection of relapse after bone marrow transplantation in patients with chronic myelogenous leukaemia.

1 reference

https://api.crossref.org/works/10.1016%2FS0889-8588%2805%2970496-2

7 January 2021

Quantitative determination of the hybrid Bcr-Abl RNA in patients with chronic myelogenous leukaemia under interferon therapy

1 reference

https://api.crossref.org/works/10.1016%2FS0889-8588%2805%2970496-2

7 January 2021

Blastic transformation in chronic myelogenous leukemia: Experience with 50 patients

1 reference

https://api.crossref.org/works/10.1016%2FS0889-8588%2805%2970496-2

7 January 2021

Allogeneic bone marrow transplantation for chronic myeloid leukemia using sibling and volunteer unrelated donors. A comparison of complications in the first 2 years

1 reference

https://api.crossref.org/works/10.1016%2FS0889-8588%2805%2970496-2

7 January 2021

Autologous transplants for chronic myelogenous leukaemia: results from eight transplant groups

1 reference

https://api.crossref.org/works/10.1016%2FS0889-8588%2805%2970496-2

7 January 2021

Randomized trial of splenectomy in Ph1-positive chronic granulocytic leukaemia, including an analysis of prognostic features

1 reference

https://api.crossref.org/works/10.1016%2FS0889-8588%2805%2970496-2

7 January 2021

Alpha 2 interferon in chronic myeloid leukaemia following relapse post-allogeneic transplant

1 reference

https://api.crossref.org/works/10.1016%2FS0889-8588%2805%2970496-2

7 January 2021

Practical guidelines for the management of chronic myelogenous leukemia with interferon alpha

1 reference

https://api.crossref.org/works/10.1016%2FS0889-8588%2805%2970496-2

7 January 2021

Interstitial pulmonary fibrosis following busulfan therapy

1 reference

https://api.crossref.org/works/10.1016%2FS0889-8588%2805%2970496-2

7 January 2021

Standard conditioning regimen and T-depleted donor bone marrow for transplantation in chronic myeloid leukemia

1 reference

https://api.crossref.org/works/10.1016%2FS0889-8588%2805%2970496-2

7 January 2021

Busulfan lung. Report of two cases and review of the literature

1 reference

https://api.crossref.org/works/10.1016%2FS0889-8588%2805%2970496-2

7 January 2021

Lens changes in chronic granulocytic leukemia. Possible relationship to chemotherapy

1 reference

https://api.crossref.org/works/10.1016%2FS0889-8588%2805%2970496-2

7 January 2021

Induction of graft-versus-host disease as immunotherapy for relapsed chronic myeloid leukemia

1 reference

https://api.crossref.org/works/10.1016%2FS0889-8588%2805%2970496-2

7 January 2021

Philadelphia-chromosome-positive adult acute lymphocytic leukemia: characteristics, treatment results, and prognosis in 41 patients

1 reference

https://api.crossref.org/works/10.1016%2FS0889-8588%2805%2970496-2

7 January 2021

Clinical toxicity of interferons in cancer patients: a review

1 reference

https://api.crossref.org/works/10.1016%2FS0889-8588%2805%2970496-2

7 January 2021

Autologous blood stem cell transplantation for chronic granulocytic leukaemia in transformation: a report of 47 cases.

1 reference

https://api.crossref.org/works/10.1016%2FS0889-8588%2805%2970496-2

7 January 2021

Treatment of excessive thrombocythemia in chronic myeloid leukemia by thrombocytopheresis and intravenous Thio-TEPA

1 reference

https://api.crossref.org/works/10.1016%2FS0889-8588%2805%2970496-2

7 January 2021

Chronic granulocytic leukaemia: comparison of radiotherapy and busulphan therapy. Report of the Medical Research Council's working party for therapeutic trials in leukaemia

1 reference

https://api.crossref.org/works/10.1016%2FS0889-8588%2805%2970496-2

7 January 2021

Hematologic remission and cytogenetic improvement after treatment of stable-phase chronic myelogenous leukemia with continuous infusion of low-dose cytarabine

1 reference

https://api.crossref.org/works/10.1016%2FS0889-8588%2805%2970496-2

7 January 2021

Autoimmunity after alpha-interferon therapy for malignant carcinoid tumors

1 reference

https://api.crossref.org/works/10.1016%2FS0889-8588%2805%2970496-2

7 January 2021

Leukocyte alkaline phosphatase. Fluctuations with disease status in chronic granulocytic leukemia

1 reference

https://api.crossref.org/works/10.1016%2FS0889-8588%2805%2970496-2

7 January 2021

A proposed staging system for chronic myeloid leukemia

1 reference

https://api.crossref.org/works/10.1016%2FS0889-8588%2805%2970496-2

7 January 2021

Letter: A new consistent chromosomal abnormality in chronic myelogenous leukaemia identified by quinacrine fluorescence and Giemsa staining

1 reference

https://api.crossref.org/works/10.1016%2FS0889-8588%2805%2970496-2

7 January 2021

Hydroxyurea versus busulfan in the treatment of chronic myelogenous leukemia

1 reference

https://api.crossref.org/works/10.1016%2FS0889-8588%2805%2970496-2

7 January 2021

An extrinsic factor controls neutrophil alkaline phosphatase synthesis in chronic granulocytic leukaemia

1 reference

https://api.crossref.org/works/10.1016%2FS0889-8588%2805%2970496-2

7 January 2021

Low doses of interferon-alpha are as effective as higher doses in inducing remissions and prolonging survival in chronic myeloid leukemia

1 reference

https://api.crossref.org/works/10.1016%2FS0889-8588%2805%2970496-2

7 January 2021

Thioguanine used in maintenance therapy of chronic myeloid leukaemia causes non-cirrhotic portal hypertension. Results from MRC CML. II. Trial comparing busulphan with busulphan and thioguanine

1 reference

https://api.crossref.org/works/10.1016%2FS0889-8588%2805%2970496-2

7 January 2021

Preferential inhibition by cytarabine of CFU-GM from patients with chronic granulocytic leukemia

1 reference

https://api.crossref.org/works/10.1016%2FS0889-8588%2805%2970496-2

7 January 2021

Priapism complicating chronic granulocytic leukemia

1 reference

https://api.crossref.org/works/10.1016%2FS0889-8588%2805%2970496-2

7 January 2021

Interferon-alpha produces sustained cytogenetic responses in chronic myelogenous leukemia. Philadelphia chromosome-positive patients

1 reference

https://api.crossref.org/works/10.1016%2FS0889-8588%2805%2970496-2

7 January 2021

Human leukocyte interferon to control thrombocytosis in chronic myelogenous leukemia

1 reference

https://api.crossref.org/works/10.1016%2FS0889-8588%2805%2970496-2

7 January 2021

Hematologic remission and cytogenetic improvement induced by recombinant human interferon alpha A in chronic myelogenous leukemia

1 reference

https://api.crossref.org/works/10.1016%2FS0889-8588%2805%2970496-2

7 January 2021

Bone marrow hypoplasia and aplasia complicating interferon therapy for chronic myelogenous leukemia

1 reference

https://api.crossref.org/works/10.1016%2FS0889-8588%2805%2970496-2

7 January 2021

Persistence of dormant leukemic progenitors during interferon-induced remission in chronic myelogenous leukemia. Analysis by polymerase chain reaction of individual colonies

1 reference

https://api.crossref.org/works/10.1016%2FS0889-8588%2805%2970496-2

7 January 2021

A phase II study alternating alpha-2a-interferon and gamma-interferon therapy in patients with chronic myelogenous leukemia

1 reference

https://api.crossref.org/works/10.1016%2FS0889-8588%2805%2970496-2

7 January 2021

Clinical and prognostic features of patients with Philadelphia chromosome-positive chronic myelogenous leukemia and extramedullary disease

1 reference

https://api.crossref.org/works/10.1016%2FS0889-8588%2805%2970496-2

7 January 2021

Treatment of 11 patients with chronic myelogenous leukemia with interferon-alpha-2C and low-dose cytosine arabinoside

1 reference

https://api.crossref.org/works/10.1016%2FS0889-8588%2805%2970496-2

7 January 2021

Interferon-alpha-2C and LD ara-C for the treatment of patients with CML: Results of the austrian multicenter phase II study

1 reference

https://api.crossref.org/works/10.1016%2FS0889-8588%2805%2970496-2

7 January 2021

Staging of chronic myeloid leukaemia

1 reference

https://api.crossref.org/works/10.1016%2FS0889-8588%2805%2970496-2

7 January 2021

Interferon-alpha restores the deficient expression of the cytoadhesion molecule lymphocyte function antigen-3 by chronic myelogenous leukemia progenitor cells

1 reference

https://api.crossref.org/works/10.1016%2FS0889-8588%2805%2970496-2

7 January 2021

Therapy of lymphoid and undifferentiated chronic myelogenous leukemia in blast crisis with continuous vincristine and adriamycin infusions plus high-dose decadron

1 reference

https://api.crossref.org/works/10.1016%2FS0889-8588%2805%2970496-2

7 January 2021

Combination therapy with interferon alpha-2b plus low-dose interferon gamma in pretreated patients with Ph-positive chronic myelogenous leukaemia

1 reference

https://api.crossref.org/works/10.1016%2FS0889-8588%2805%2970496-2

7 January 2021

Bone marrow histology. 3: Value of bone marrow core biopsy in acute leukaemia, myelodysplastic syndromes, and chronic myeloid leukaemia

1 reference

https://api.crossref.org/works/10.1016%2FS0889-8588%2805%2970496-2

7 January 2021

10.1016/S0889-8588(05)70496-2

Identifiers

DOI

1 reference

8 October 2017

1 reference